Semaglutide Adjunct to Intragastric Balloon Enhances 12-Month Weight Loss

Overview

This 12-month prospective study compared weight loss outcomes in obese patients receiving intragastric balloon (IGB) therapy alone versus IGB combined with semaglutide. The combination therapy group demonstrated superior weight reduction, suggesting a synergistic effect of semaglutide with IGB treatment.

Background

Obesity is a growing global health issue linked to increased morbidity and mortality. While lifestyle interventions are foundational, their long-term effectiveness is limited, and bariatric surgery remains underutilized due to cost and access barriers. Endoscopic bariatric therapies like intragastric balloons offer less invasive alternatives. Semaglutide, a GLP-1 receptor agonist, is an approved pharmacotherapy for obesity that promotes weight loss and may enhance outcomes when combined with IGB.

Data Highlights

Note: Exact numerical data on weight loss percentages and BMI changes were not provided in the source text.

Key Findings

• Patients receiving combined IGB and semaglutide therapy had greater weight loss compared to IGB alone over 12 months.
• The semaglutide dosing was initiated at 0.5 mg weekly in month 2, escalated to 1 mg weekly during months 3 and 4, paused during months 5 and 6, and resumed at 1 mg weekly during months 7 and 8.
• IGB was maintained for six months before removal, with semaglutide administration timed to complement balloon placement and removal phases.
• Both groups received standardized dietary counseling and lifestyle modification support throughout the study.
• The study design was prospective, randomized, and open-label with 40 patients completing 12-month follow-up.

Clinical Implications

Combining semaglutide with intragastric balloon therapy may enhance weight loss outcomes beyond IGB alone, offering a less invasive yet effective obesity treatment option. Clinicians should consider integrating GLP-1 receptor agonists like semaglutide in patients undergoing endoscopic bariatric procedures to optimize results. Careful dosing schedules aligned with balloon placement can maximize efficacy while minimizing adverse effects.

Conclusion

The adjunct use of semaglutide with intragastric balloon therapy shows promise in improving weight loss outcomes in obese patients. This combined approach warrants further investigation as a viable strategy in obesity management.

References

1. Obesity and related morbidity -- Global health burden
2. Look AHEAD Study -- Long-term weight loss outcomes
3. Semaglutide approval and efficacy -- GLP-1 RA in obesity
4. Endoscopic bariatric therapies -- Intragastric balloons